Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.”
Email: jackfriday2011(at)hotmail.co.uk
Friday, May 28, 2010
FDA Staff Sees Allergic-Reaction Risk With AZ's motavizumab
"We clearly have a safety signal suggesting motavizumab has more significant hypersensitivity reactions than palivizumab [Synagis]," the FDA said. The agency said the product has three times as many allergic reactions as Synagis.
No comments:
Post a Comment